SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Anuh Pharma - Quaterly Results

07 Feb 2026 Evaluate
The December 2025 quarter revenue stood at Rs. 1971.78 millions, up 23.61% as compared to Rs. 1595.13 millions during the corresponding quarter last year.The company has announced a 30.05% increase in its profits to Rs . 134.52  millions for the  quarter ended December 2025 compared to Rs. 103.44 millions in the corresponding quarter in the previous year.The company reported a good operating profit of 209.11 millions compared to 157.27 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 1971.78 1595.13 23.61 5695.40 4633.75 22.91 6615.15 6470.04 2.24
Other Income 41.10 9.38 338.17 84.76 80.57 5.20 94.55 120.98 -21.85
PBIDT 209.11 157.27 32.96 474.47 502.94 -5.66 703.64 872.47 -19.35
Interest 0.80 2.80 -71.43 3.67 5.86 -37.37 6.19 3.54 74.86
PBDT 208.31 154.47 34.85 470.80 497.08 -5.29 697.45 868.93 -19.73
Depreciation 30.02 21.81 37.64 83.79 59.83 40.05 87.39 85.84 1.81
PBT 178.29 132.66 34.40 387.01 437.25 -11.49 610.06 783.09 -22.10
TAX 43.77 29.22 49.79 93.37 88.30 5.74 136.53 182.52 -25.20
Deferred Tax -5.97 -2.58 131.40 -9.27 -10.60 -12.55 -16.52 3.59 -560.17
PAT 134.52 103.44 30.05 293.64 348.95 -15.85 473.53 600.57 -21.15
Equity 501.12 250.56 100.00 501.12 250.56 100.00 250.56 250.56 0.00
PBIDTM(%) 10.61 9.86 7.56 8.33 10.85 -23.25 10.64 13.48 -21.12

Anuh Pharma Share Price

81.99 -0.11 (-0.13%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.20
Dr. Reddys Lab 1322.95
Cipla 1309.90
Zydus Lifesciences 891.65
Lupin 2303.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×